Skip to content
Jens Spahn

Jens Spahn

Not rated

Jens Georg Spahn is a German politician of the Christian Democratic Union (CDU) who has represented the constituency of Steinfurt I – Borken I in the Bundestag since 2002. From May 2025 until his resignation in July 2026, he served as leader of the joint CDU/CSU (Union) parliamentary group in the 21st Bundestag.

  • Facts0
  • Drivers0
  • Indicators0

Evidence & methodology

How the record is sourced and how the score is derived.

The score is formula-derived (Factrail formula v1, version 1.0.0), not an editorial verdict. Read the methodology.

By the · Method: how we source and score · Last reviewed

Expert analysis

An excerpt; the full analysis opens on request.

Health ministry leadership during the COVID-19 emergency

Jens Spahn served as Germany's federal health minister from 2018 to 2021, overseeing an institution under enormous pressure during the first years of the coronavirus pandemic. The Bundestag's account of later inquiries (opens in a new tab) identifies Spahn as the former minister at the center of scrutiny over protective-mask purchasing. Emergency procurement created a genuine policy dilemma: governments had to obtain medical supplies quickly under uncertain future demand, while protecting the public budget from waste and weak contracting controls. These two concerns do not cancel each other out. Understanding the period requires examining purchasing decisions against the information available at the time, and distinguishing broad ministerial responsibility from which contracts were negotiated by officials and suppliers.

Procurement oversight, evidence and competing explanations

At the December 2025 parliamentary hearing (opens in a new tab), Spahn argued that policymakers faced pressure to procure centrally and did not know how many future infection waves would follow. Critics questioned oversupply and contracting judgments. The July committee account (opens in a new tab) noted that the special investigator had sharply criticized the purchasing approach and that litigation continued to threaten public funds. These are findings about an administrative controversy; they do not establish that every questioned contract was illegal. A useful assessment asks whether procurement rules, records of supplier selection and subsequent judicial decisions substantiate specific failures. It must also retain the countervailing context of the public-health emergency. The observable consequence was sustained parliamentary oversight and budgetary exposure, rather than an automatic criminal judgment.